ISPOR 2025

Share on:

Tuesday, May 13 - Friday, May 16, 2025

Conference website

Montreal Convention Centre
1001 Place Jean-Paul-Riopelle,
Métro Place-d'Armes
Montreal QC H2Z 2B3
Canada

Collaborating to Improve Healthcare Decision Making for All: Expanding HEOR Horizons

Our team of experts is looking forward to this year's ISPOR conference in Montreal - renowned for its unique blend of European charm and North American flair, boasting a rich history, diverse culture, captivating architecture, a vibrant culinary scene, and iconic attractions like Old Montreal, Mount Royal, and the Underground City.

Most importantly, it's the city where you'll be able to take in our research and visit with our world-renowned research experts.

Take a look below to see what research we're presenting and which researchers will be attending and visit us at booth 1806.

Preconference Short Courses | May 13
All times are listed in Eastern Time Zone (ET)

May 13

8:00 am-12:00 pm

Advanced patient-reported outcomes. Mastering Patient-Reported Outcomes (PRO) in Drug Development. Gnanasakthy A, Crawford R, Qin S, Doward L, Rockwood NJ.

Symposium & Workshop
All times are listed in Eastern Time Zone (ET)

Advancing accuracy and transparency in health economic evaluation. Brogan A.

Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Herring WL, Coon C, Lenderking W, Whittington M.

From data to dialogue: mastering conversations to amplify HEOR impact and influence. Brogan A, Zhang K.

Presentation
All times are listed in Eastern Time Zone (ET)

Alternative recruitment options for patient preference studies: thinking outside the market research panel box. Bozzi LM, Johnson R, Heidenreich S, Poulos C.

Climbing the HEOR career ladder: strategies for success in an era of change. Pizzi L, Earnshaw S, Blanchette C, Thompson D.

Clinical trial design, beyond the regulatory. Copley-Merriman K, Doward L, Hawe E, Cope S.

Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Riemer J, Campbell K, Arthurs E, Knight C.

Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N.

Interventions to improve adherence and persistence to oral medication: a targeted literature review. Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M.

Poster sessions | Dates and Time TBA

A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ.

Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A.

Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K.

Assessing the impact of the United States (US) Inflation Reduction Act (IRA) regulations on investment incentives for orphan disease drug development. Ronquest N, Zhang Y, Mladsi D.

Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S.

Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN.

Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED.

Estimates of the public health impact of norovirus vaccination for older adults in the United States. Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO.

Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Marcano Belisario J, Lunan M, Hawe E, Farrelly G.

Over 30 years of discrete choice experiment studies in health economics: systematic review of current practice and reflections on evolving practice. Loria-Rebolledo L, Watson V, Mohan D, Vass CM, Antunes M, Burns D, Ryan M.

The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P.

The most heavily managed drug categories on Part D formularies. Buck PM, Masaquel C.

The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P.

Use of diaries to capture patient-reported outcomes in FDA new drug approvals (2019-2023). Sauchelli S, Chicklis EK, Carty MK, Gnanasakthy A.

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F.

Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F.

Interventions to improve adherence and persistence to oral medication: a targeted literature review. Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M.

Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N.

Poster session 1 | May 14, 10:30-1:30 pm

Poster session 2 | May 14, 4:00-7:00 pm

Poster session 3 | May 15, 10:30-1:30 pm

Poster session 4 | May 15, 4:00-7:00 pm

Poster session 5 | May 16, 9:00-11:30 am

Meet up with our experts

Susan Barker, BA

Senior Director, Marketing-Digital Strategy

Bonita Basnyat, PhD

Senior Research Scientist, Patient-Centered outcomes Assessment

Anita Brogan, PhD

Vice President, Decision Analytic Modeling, Health Economics

Chase Brown

Chase Brown, MS

Business Development Specialist

Sarah Calhoun, MBA

Senior Director, Surveys and Observational Studies

Kati Copley-Merriman, MBA

Vice President, Value and Access Lead

Rebecca Crawford, MA

Director, Patient-Centered Outcomes Assessment

Gabrielle J. Dardis, PhD

Medical Writer

Ashley Davis, PhD

Senior Director, Health Economics

Tosca Dekkers

Tosca Dekkers, MA

Vice President, Strategic Client Engagement

Amanda Di Rosa, PhD

Senior Associate, Value and Access

Lynda Doward, MRes

VP, European Head Patient-Centered Outcomes Assessment

Stephanie Earnshaw, PhD

Senior Fellow

David Fontaine, BS

Director, Business Development

Ari Gnanasakthy, MBA, MSc

Principal Scientist, Patient-Centered Outcomes Assessment

Audra Gold, MSc

Senior Research Scientist

Ravi Goyal, PhD

Senior Director, Health Economics

Nimanee Harris, MPH

Senior Research Scientist, Patient-Centered Outcomes Assessment

William L Herring, PhD

Executive Director, Health Economics

Maria Jimenez, MPH

Associate Director, Health Economics

Siddharth Karanth, DrPH

Director, Health Economics

Catherine Masaquel, MPH

Senior Director, Value and Access

AJ Messina

AJ Messina, MSHS

Head, Implementation Science

Dee Dee Mladsi, BA

Vice President, Health Economics—Strategy and Early Modeling

Margaret Mordin, MS

Vice President, Value and Access

Mark Morrison, BS

Director, Business Development

Christine Poulos, PhD

Senior Economist and Vice President, Health Preference Assessment

Shanshan Qin, PhD

Senior Director, Psychometrics, Patient-Centered Outcomes Assessment

Nicholas Rockwood

Nicholas Rockwood, PhD

Director, Patient-Centered Outcomes Assessment

Naoko Ronquest, PhD

Executive Director, US HTA Strategy and Early Modeling

Cassondra Saande

Cassondra Saande, PhD

Senior Medical Writer

Bintu Sherif, MS

Senior Director, Biostatistics

Verity Watson, PhD

Senior Research Economist

Peter Wirth, BS

Vice President, Business Development

Kate Zhang, PharmD

Associate Director, Health Economics